FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:1304-1306 September 24, 2009 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Olanow, C. W. PubMed Citation

To advance our understanding of treatments for diseases that progress slowly but that are ultimately debilitating, such as Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, and chronic obstructive pulmonary disease, it is essential to evaluate the disease-modifying effects of administered treatments. It is also essential to separate these effects from the short-term beneficial effects on symptoms that such treatments may provide. This separation of improvement in symptoms from a change in primary disease progression can be difficult.

One such approach is the delayed-start design (also called the randomized-start design).¹ Although there has been regulatory support for this approach,² there have been . . . [Full Text of this Article]

Source Information

From the Mathematics and Statistics Department, Boston University, Boston.

Address reprint requests to Dr. D'Agostino at the Mathematics and Statistics Department, Boston University, 111 Cummington St., Boston, MA 02215, or at ralph@bu.edu.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.